Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna

Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna

Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

Studies supporting the application had a mysterious difference in outcomes. Further analysis of virologic failures is under way, says lead investigator.

Related Content

Topics

UsernamePublicRestriction

Register

PS066764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel